.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, people with metastatic intestinal cysts who acquired biomarker-matched treatments based on flowing tumor DNA profiling presented a more significant professional benefit than those getting unparalleled treatment.